Subscribe

ESMO 2014 - Gastrointestinal and Head & Neck Cancer

The AIO 1108 study was an open-label, randomized, multicenter trial that evaluated the efficacy and tolerability of cetuximab, fluorouracil, cisplatin (PFC) plus docetaxel (PFCD) versus a standard PFC regimen in patients with recurrent or metastatic head and neck squamous-cell carcinoma (SCC).
Recurrent or metastatic head and neck squamous-cell carcinoma (SCC) is associated with a poor prognosis, and the treatment options are limited in this disease setting, highlighting the need for novel treatment strategies.
The randomized phase 3 IMCL-9815 trial demonstrated that the addition of cetuximab to radiotherapy improved locoregional control (LRC) and overall survival (OS) in patients with locoregionally advanced squamous-cell carcinoma (SCC) of the head and neck.
Recurrent and metastatic head and neck squamous-cell carcinoma (SCC) is associated with a poor prognosis, and the treatment options are limited in this disease setting, highlighting the need for novel treatment strategies.
The phase 3 CALGB/SWOG 80405 clinical trial analyzed the clinical benefit of the addition of cetuximab or bevacizumab to first-line chemotherapy with FOLFOX or FOLFIRI in KRAS wild-type (codons 12 and 13) in 1137 patients with metastatic colorectal cancer.
Tivozanib is a selective oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor with a long half-life and potency against all 3 VEGF receptors. Tivozanib in combination with a modified fluoropyrimidine, folinic acid, and oxaliplatin (mFOLFOX6) regimen was shown to be well-tolerated and active in patients with metastatic colorectal cancer (mCRC).
Monoclonal antibodies (MoAbs) targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) in combination with first-line doublet chemotherapy have demonstrated considerable clinical activity in metastatic colorectal cancer (mCRC).
The phase 3 New EPOC study randomized patients with resectable or suboptimally resectable colorectal liver metastases (CRLM) and KRAS exon 2 wild-type disease status to receive chemotherapy with or without the anti–epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab (Bridgewater J, et al. EPOC study. ESMO 2014: Abstract 542P).
The CRYSTAL study demonstrated that the addition of cetuximab to first-line chemotherapy significantly improved clinical outcomes, specifically for patients with RAS wild-type metastatic colorectal cancer (mCRC).
Although both cetuximab and bevacizumab have separately demonstrated improvements in clinical outcomes in patients with metastatic colorectal cancer (mCRC) when added to first-line chemotherapy regimens, their comparative efficacies in combination with fluorouracil, folinic acid, and irinotecan (FOLFIRI) are unknown.
Page 1 of 2
Results 1 - 10 of 19
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology